Navigation Links
Cantel Medical's Crosstex Subsidiary Launches New Specially Treated Face Mask Effective Against H1N1 Influenza

LITTLE FALLS, N.J., Oct. 13 /PRNewswire-FirstCall/ -- CANTEL MEDICAL CORP. (NYSE: CMN), through its Crosstex International subsidiary, has launched a unique face mask treated with BIOSAFE(®) antimicrobial in markets outside the United States. Crosstex' new BIOSAFE-treated Ultra Sensitive face masks begin to reduce microorganisms, such as MRSA, VRE and Staph, immediately upon contact. These treated face masks have proven to be effective against Influenza A strains, such as seasonal flu and the novel H1N1 virus.

Gary Steinberg, CEO of Crosstex, stated, "Face masks serve as the first line of defense against airborne particles by trapping them in the filter media. However, live microorganisms can continue to live on the mask surface. Our new BIOSAFE-treated Ultra Sensitive face masks enhance the functionality of the mask by effectively killing the harmful microorganisms, reducing the cross-contamination risk from touching the mask itself and creating a safer environment upon disposal of the mask. The BIOSAFE treatment additive, as approved by the EPA, is compatible with our manufacturing process. We are impressed that the BIOSAFE treatment chemically binds to the outer mask surface, creating a long-lasting shield against microbial contamination. Even better, because BIOSAFE mechanically kills cells, it will not cause the development of more resistant 'superbugs'."

Cantel's President and CEO, Andrew Krakauer, explained, "BIOSAFE is an important component of our strategic plan to expand our liquid chemical germicide business and invest more aggressively in research and development. Given the unique performance, manufacturability and cost advantages of this additive, Cantel has embarked on a number of internal R&D initiatives to incorporate BIOSAFE into additional infection prevention and control products." Mr. Krakauer continued, "We have invested significant dollars, resources and time towards this goal, and it has been a superb cross-divisional effort that demonstrates how we are gaining leverage from expertise in our various companies."

Within the United States, the sale of face masks treated with BIOSAFE antimicrobial for medical applications is subject to a 510(k) clearance by the U.S. Food and Drug Administration. At this time, the Company is awaiting publication of the latest revision of the FDA Guidance Document pertaining to antimicrobial treatments of medical devices prior to the filing of its 510(k) Premarket Notification submission. The Company is in the process of submitting an application to the U.S. Environmental Protection Agency covering the sale of treated masks in the United States for non-medical applications.

About BIOSAFE, Inc.

Pittsburgh-based BIOSAFE, Inc. manufactures and sells an antimicrobial polymer, HM 4100. HM4100 is effective in defending against bacteria, fungi (mold and mildew), yeast, algae and even certain viruses. BIOSAFE's patented technology is an excellent antimicrobial additive for treating plastics, textiles, metals, ceramics, and activated carbon, with superior performance and economic benefits. For further information, visit the BIOSAFE website at

About Crosstex International, Inc.

A division of Cantel Medical Corp., Crosstex manufactures a wide array of infection prevention and control products for the healthcare industry. Founded in 1953 and headquartered in Hauppauge, New York, Crosstex sells branded and private label products including face masks, which are 100% manufactured in its FDA-registered New York facility. Sold in more than 100 countries, Crosstex products include sterilization pouches and accessories, patient towels and bibs, eyewear, surface disinfectants and deodorizers, germicidal wipes, hand sanitizers, gloves, sponges, cotton products, needles and syringes, scalpels and blades, sharps containers, saliva ejectors and evacuator tips. For further information, visit the Crosstex website at

About Cantel Medical Corp.

Cantel Medical Corp. (NYSE: CMN) is a leading provider of infection prevention and control products in the healthcare market. Our products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection prevention and control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens. For more information please visit

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.

SOURCE Cantel Medical Corp.

SOURCE Cantel Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
2. Cantel Medical Corp. To Hold Conference Call To Discuss Fourth Quarter and Fiscal 2009 Results
3. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
4. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
5. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
6. New Places and People - Truphatek opens USA subsidiary
7. Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medicals Subsidiary, Sanvita, Inc.
8. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
9. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Marker Testing Market: Supplier Shares, ... their offering.  --> ... the  "2016 Future Horizons and Growth ...
Breaking Medicine Technology:
(Date:11/29/2015)... Los Angeles, Ca (PRWEB) , ... November 29, 2015 , ... ... from the American Board of Ophthalmology on November 25th 2015. Peer Certification ... in the field of his specialty. Certification in Ophthalmology is first obtained after the ...
(Date:11/29/2015)... ... November 29, 2015 , ... Effective immediately, every single IguanaMed scrub ... on Black Friday Target is offering a “Buy One Scrub Set, Get the 2nd ... opportunity to purchase IguanaMed at a discounted price. , IguanaMed’s mission is ...
(Date:11/28/2015)... ... November 28, 2015 , ... Trying to relax on a couch ... BUDDY. "I conceived of this design due to personal experience with a bad back," ... promotes relaxation and convenience, as well as increases support. It also makes it easier ...
(Date:11/27/2015)... , ... November 27, 2015 , ... According to an ... recent 2015 American Dental Association meeting in Washington D.C. revolved around the fact that ... patient’s overall health. The talk stressed the link between periodontal disease (more commonly referred ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has released ... Surviving Mesothelioma has just posted the findings on the website. Click here to ... cases of 136 mesothelioma patients who were treated with chemotherapy followed by EPP surgery. ...
Breaking Medicine News(10 mins):